Argos Therapeutics
Manufacturing · Vietnam · 1-10 Employees
View Company Info for Free
Overview
Headquarters
62 Tố Hữu Lô Sh20, Huế, Thừa Thiên Huế, ...Website
www.argostherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Argos Therapeutics
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North...Explore more
Argos Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Argos Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Argos Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Argos Therapeutics
Product Launch: Get notified when Argos Therapeutics launches new products
Check if Argos Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Argos Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Argos Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Argos Therapeutics has new funding data
Earning: See what the market has to say on Argos Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Argos Therapeutics
Find more new buyers
Compare Similar Companies to Argos Therapeutics
Compare insights from companies similar to Argos Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Argos Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Argos Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Argos Therapeutics.
Argos Therapeutics financials insights
Gather financial insights about Argos Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Debt
$3.5M
2012
Series D
$25M
Private Equity
$16M
2013
Series E
$42.5M
2014
Stock Offering
$45M
2016
Share Placement
$29.8M
2017
Share Placement
$6M
2018
Private Equity
$1.5M
Argos Therapeutics Tech Stack
A closer look at the technologies used by Argos Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Argos Therapeutics
Sign Up For FreeTo access detailed company insights
Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, whi... Read More
